CELCUITY INC (CELC) Stock Price, Forecast & Analysis
NASDAQ:CELC • US15102K1007
CELC Key Statistics, Chart & Performance
The current stock price of CELC is 107.6 USD. In the past month the price increased by 0.34%. In the past year, price increased by 716.12%.
CELC Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CELC. When comparing the yearly performance of all stocks, CELC is one of the better performing stocks in the market, outperforming 99.65% of all stocks.
CELC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CELC. The financial health of CELC is average, but there are quite some concerns on its profitability.
CELC Financial Highlights
Over the last trailing twelve months CELC reported a non-GAAP Earnings per Share(EPS) of -3.67. The EPS decreased by -40.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.19% | ||
| ROE | -139.12% | ||
| Debt/Equity | 2.74 |
CELC Forecast & Estimates
17 analysts have analysed CELC and the average price target is 112.71 USD. This implies a price increase of 4.75% is expected in the next year compared to the current price of 107.6.
CELC Ownership
CELC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.64 | 411.552B | ||
| AMGN | AMGEN INC | 16.82 | 201.047B | ||
| GILD | GILEAD SCIENCES INC | 17.19 | 192.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.2 | 121.106B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 83.892B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.67 | 43.941B | ||
| INSM | INSMED INC | N/A | 32.101B | ||
| NTRA | NATERA INC | N/A | 29.393B | ||
| BIIB | BIOGEN INC | 12.84 | 28.709B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.24 | 20.773B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CELC
Company Profile
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Company Info
CELCUITY INC
16305 36th Ave N Ste 100
Minneapolis MINNESOTA 55446 US
CEO: Brian F. Sullivan
Employees: 87
Phone: 13026587581
CELCUITY INC / CELC FAQ
What does CELCUITY INC do?
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Can you provide the latest stock price for CELCUITY INC?
The current stock price of CELC is 107.6 USD. The price increased by 0.26% in the last trading session.
What is the dividend status of CELCUITY INC?
CELC does not pay a dividend.
What is the ChartMill technical and fundamental rating of CELC stock?
CELC has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CELC stock?
CELC stock is listed on the Nasdaq exchange.
Is CELCUITY INC (CELC) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CELC.
Who owns CELCUITY INC?
You can find the ownership structure of CELCUITY INC (CELC) on the Ownership tab.